secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aprea Therapeutics, Inc. (APRE)
CIK:        0001781983
Form:       8-K
Filed at:   2023-04-18T23:59:59+00:00
Accession:  0001104659-23-046719
Event type: other_material
Sentiment:  neutral
Materiality: 0.25
Item codes: 4.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aprea Therapeutics dismisses EY, appoints EisnerAmper as new independent auditor
--------------------------------------------------------------------------------

- On April 17, 2023, Aprea dismissed Ernst & Young LLP as its independent auditor, effective immediately.
- The Audit Committee approved the dismissal and engagement of EisnerAmper LLP as new auditor for FY 2023.
- EY's reports for 2022 and 2021 contained no adverse opinion or qualification; no disagreements or reportable events existed.
- No consultations with EisnerAmper occurred prior to engagement on any accounting matters.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1781983/000110465923046719/0001104659-23-046719-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1781983/000110465923046719/tm2312947d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-046719

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer